Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory clinical study to evaluate the efficacy and safety of prasugrel monotherapy using computed tomography-derived fractional flow reserve (CT-FFR) after undergoing PCI in patients for whom long-term dual antiplatelet therapy with aspirin is not recommended

Trial Profile

Exploratory clinical study to evaluate the efficacy and safety of prasugrel monotherapy using computed tomography-derived fractional flow reserve (CT-FFR) after undergoing PCI in patients for whom long-term dual antiplatelet therapy with aspirin is not recommended

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prasugrel (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 03 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top